Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer

Gilead gets Trodelvy FDA priority review for pre-treated HR+/HER2- metastatic breast cancer

Gilead Sciences said that Trodelvy (sacituzumab govitecan-hziy) has been granted priority review from the US Food and Drug Administration (FDA) for the treatment of another type of metastatic breast cancer. The supplemental biologics license application (sBLA) filed by Gilead Sciences is for using the breast cancer drug in adults having unresectable locally advanced or metastatic […]

AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer

AstraZeneca, Daiichi Sankyo get Enhertu FDA approval for HER2-low metastatic breast cancer

Enhertu FDA approval : AstraZeneca and Daiichi Sankyo have secured approval for Enhertu (trastuzumab deruxtecan) from the US Food and Drug Administration for the treatment of a type of metastatic breast cancer in adult patients. Enhertu is said to be a specifically engineered HER2-directed antibody drug conjugate (ADC). It is being co-developed and commercialized by […]

BriaCell Therapeutics’ Bria-IMT gets FDA fast track status in breast cancer

BriaCell Therapeutics’ Bria-IMT gets FDA fast track status in breast cancer

BriaCell Therapeutics has secured the fast track status from the US Food and Drug Administration (FDA) for its lead candidate — Bria-IMT for the treatment of metastatic breast cancer. The US-based clinical-stage biotech company specializes in targeted immunotherapies for cancer. Bria-IMT is a cell-based immunotherapy, which has been designed to preferentially kill tumor cells without […]

Alphamab Oncology enrols patients for KN026-203 phase 2 clinical trial

Alphamab Oncology enrols patients for KN026-203 phase 2 clinical trial

Alphamab Oncology said that it has completed enrolling patients in China for its KN026-203 phase 2 clinical trial of the combination of KN026 and KN046 in the treatment of HER2-positive solid tumors. While KN026 is a HER2 bispecific antibody developed by the Chinese clinical-stage biopharma company, KN046 is a PD-L1/CTLA-4 bispecific antibody, developed by Jiangsu […]

Roche launches Elecsys Anti-p53 immunoassay to help in cancer diagnosis

Roche launches Elecsys Anti-p53 immunoassay to help in cancer diagnosis

Swiss healthcare company Roche has launched the Elecsys Anti-p53 immunoassay to help in the diagnosis of various types of cancer by the in vitro quantitative determination of anti-p53 antibodies. The Anti-p53 immunoassay test will help physicians in diagnosing oesophageal cancer, breast cancer, and bowel cancer in patients, in combination with other diagnostic tests, said Roche. […]

Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer

Olema Oncology to evaluate OP-1250, palbociclib combo in advanced breast cancer

Olema Oncology has entered into a clinical trial agreement with Pfizer to evaluate its small molecule OP-1250 in combination with the latter’s palbociclib (IBRANCE) in advanced breast cancer. OP-1250 is an estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). Its combination with the Pfizer breast cancer drug will be assessed in the […]

Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck to acquire US biopharma company VelosBio to strengthen oncology pipeline

Merck acquisition of VelosBio : US pharma giant Merck has agreed to acquire VelosBio, a California-based clinical-stage biopharma company, for $2.75 billion in an all-cash deal, in a move to strengthen its oncology pipeline. VelosBio is engaged in developing cancer therapies that target receptor tyrosine kinase-like orphan receptor 1 (ROR1). The company’s lead investigational candidate […]